Pay in 4 interest-free payments of $6.27 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Current UK Chief Medical Officers' guidelines recommend at least 150 minutes of moderate-intensity activity weekly, plus strength training twice weekly
Rarely, are these bad enough to require someone to stop the medications
TRIUMPH-4 Phase III: 28.7% weight loss at 68 weeks highest ever recorded.Retatrutide vs Semaglutide vs TirzepatideRetatrutide: 28.7% weight loss (68 wk) Triple agonist (GLP-1+GIP+GCGR)Tirzepatide (Mounjaro/Zepbound): 22.5% (72 wk) Dual agonist (GLP-1+GIP)Semaglutide (Wegovy/Ozempic): 15-17% (68 wk) GLP-1 onlyKey Clinical Results (April 2026)TRIUMPH-4 Phase III (Dec 2025): 28.7% body weight reduction, 71.2 lbs lost at 12mg doseTRANSCEND-T2D-1 (Mar 2026): 2.0% HbA1c reduction, 16.8% weight loss in type 2 diabetesPhase II (NEJM 2023): 24.2% weight loss at 48 weeks, no plateau observedFDA NDA submission: Q4 2026-Q1 2027Research-Grade RetatrutideBioInfinity Lab GLP3-R: 99%+ purity, third-party COA verified, GMP compliant
Semaglutide is a powerful medicine that helps manage blood sugar and supports major weight loss
Use the Ozempic Savings Card If your insurance covers Ozempic but with high cost-sharing, the Novo Nordisk Savings Card can reduce your out-of-pocket cost to as little as $25 monthly
